Latest Dividends News

Iress Limited has reported a 19% increase in underlying earnings per share for its continuing business in the first half of 2025, completing a major transformation and reaffirming its full-year guidance despite revenue pressures from divestments.

JB Hi-Fi reported a robust FY25 with 10% sales growth and increased dividends, while preparing for a leadership change.

JB Hi-Fi Limited has announced a fully franked dividend of AUD 2.05 per share for the first half of FY2025, combining ordinary and special dividends payable in September.

JB Hi-Fi Limited reported a robust FY2025 with revenue up 10% to $10.55 billion and net profit after tax rising 5.4% to $462.4 million. The company declared a fully franked final dividend and a special dividend, while announcing a CEO succession plan.

Iress Limited reported a stable half-year profit for 2025, maintaining net earnings despite a slight revenue dip and ongoing divestments. The company strengthened its balance sheet through debt reduction and declared a healthy interim dividend, while exploring potential acquisition opportunities.

CAR Group Limited has reported solid full-year FY25 results with revenue surpassing AUD 1.18 billion and adjusted NPAT rising to AUD 377 million, underpinned by global marketplace strength and strategic innovation. The company projects continued double-digit growth in FY26, driven by technology investments and market expansion.

CAR Group Limited has reported strong FY25 financial results with double-digit revenue and earnings growth across all key markets, while preparing for a leadership change. The company’s optimistic FY26 outlook underscores confidence in sustained expansion driven by innovation and market leadership.

CAR Group Limited has announced a fully franked ordinary dividend of AUD 0.415 per share for the six months ending June 2025, alongside a dividend reinvestment plan offering shareholders a choice to reinvest without discount.

CAR Group Limited reported a strong FY25 with revenue up 8% to $1.18 billion and net profit after tax rising 12% to $293 million, while announcing a leadership transition as CEO Cameron McIntyre steps down.

Invex Therapeutics reports a significantly reduced net loss for FY25, driven by lower R&D costs after closing its Phase III trial, while advancing promising pre-clinical Alzheimer’s research through a collaboration with Tessara Therapeutics.

ResMed Inc. reported a robust 10% increase in revenue to $5.15 billion for fiscal 2025, driven by strong demand in sleep and breathing health devices and residential care software. The company also expanded its diagnostic capabilities with the acquisition of VirtuOx, positioning itself for further growth in home-based health solutions.

Avita Medical reported an 18% revenue increase and a 30% reduction in net loss for the first half of 2025, signaling progress as it scales commercial operations and targets profitability by 2026.